Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of VH3739937 in Healthy Participants
NCT06533280Phase 1Withdrawn
- Sponsor
- ViiV Healthcare
- Start
- Aug 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GSK3739937 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of participants with any adverse events (AEs), Number of participants with any serious adverse events (SAEs) and 4 more. Planned start Aug 2024; status: withdrawn.
02
Drugs
GSK3739937
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06533280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533280.